Introduction
Atherosclerotic renal artery hypertension is reported in almost 7% of adults older than 65 years 1) and is associated with cardiovascular events, and may double risk of mortality 2) . In the 1990s, radiological angioplasty began to replace surgical revascularization. Galaria et al. showed that percutaneous and open renal revascularization had equivalent long-term functional outcomes 3) . Over time, the less-invasive procedure became more accessible.
Most cases of atherosclerotic renovascular disease (ARVD)
are located in the ostium, and are extensions of calcified aortic plaques 4) . These lesions tend to return to their original shape with balloon angioplasty alone. Stent placement might also provide additional force to increase the rates of technical success 5) and to reduce the rate of restenosis at 6 months after the initial procedure 6) .
Intervention with stents has become a standard procedure; in patients with stenosis of the renal artery, placement of a stent is likely to be the initial form of treatment. However, there is limited evidence to support revascularization over medical therapy for patients with atherosclerotic renal artery stenosis 7, 8) .
Natural history
Retrospective studies previously reported that renal artery lesions might progress to severe stenosis and ultimately to renal artery occlusion 9) . Michael et al. performed a prospective study that reported that the progression of renal artery disease was a frequent occurrence with an annual rate of progression of renal artery lesions reported to be 7% 10) . However, at the time of these studies, statins were being used in fewer patients. A retrospective study of the effects of statins on the progression of ARVD has shown that the use of statins reduces the risk of progression and the development of ARVD 11) . Another prospective population-based study reported that the progression to significant ARVD was observed in only 4.0% during 8 years of follow-up (annualized rate, 0.5% per year), 
Dissociation between arterial patency and function
Hypertension and renal artery stenosis are not necessarily renovascular hypertension. Essential hypertension and clinically silent renal artery stenosis often coexist, and essential hypertension also coexists with renovascular hypertension 13) . This is why blood pressure control does not always improve after stenting.
Renal injury distal to an atherosclerotic renovascular obstruction is due to multiple intrinsic factors producing parenchymal tissue injury ( Fig. 1) 14)
. Non-traditional mediators of ARVD such as inflammatory pathways, reactive oxygen species production, ischemia/reperfusion damage and modulation of matrix turnover have been proposed as causes of the renal failure related to ARVD 15) .
This complexity of the pathophysiology might explain why the severity of the stenosis is not correlated with renal dysfunction. However, sometimes declining renal function is accelerated after revascularization. Possible causes of these adverse outcomes include contrast induced nephropathy, atheroembolism, and restenosis or stent thrombosis 19) . The administration of contrast might increase the risk of acute renal dysfunction, especially in patients that have preexisting renal impairment. An ex vivo study reported that each manipulation of atheroma specimens, from simply advancing the guidewire through the atherosclerotic lesion to positioning and deploying the Wallstent, releases thousands of fragments, and that these atherosclerotic fragments are of sufficient size to create vascular occlusion and initiate significant renal parenchymal damage 20) . Currently, there is no way to predict positive or negative responses after revascularization.
Factors favoring medical therapy
ARVD is a cardiovascular condition that is associated with renal artery stenosis. The nature of this disorder suggests that a systemic approach is necessary to provide cardiovascular protection.
Previously, statin therapy was discussed as a method of altering . Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers effectively reduce blood pressure in patients with renovascular disease. In addition, a population-based cohort study of over 3,500 patients with ARVD in Canada found that angiotensin inhibitors could cause acute renal toxicity in a small subset of vulnerable patients; however, they still improved the cardiovascular and renal outcomes in patients with ARVD, but at the expense of acute renal toxicity 21) .
Recently three randomized controlled trials have been , additional recommendations favoring medical therapy were as follows: very advanced age and/or limited life expectancy, extensive co-morbidities that make revascularization too risky, high risk for or previous experience with atheroembolic disease, and other concomitant renal parenchymal diseases that cause progressive renal dysfunction (e.g., interstitial nephritis, diabetic nephropathy) 23) . They also recommended factors favoring medical therapy and intervention as follows: progressive decline in GFR during treatment of systemic hypertension, failure to achieve adequate blood pressure control with optimal medical therapy (medical failure), rapid or recurrent decline in the GFR in association with a reduction in systemic pressure, decline in the GFR during therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and recurrent congestive heart failure in a patient in whom the adequacy of left ventricular function does not provide an explanation 23) . The best evidence supporting intervention is for bilateral stenosis with "flash" pulmonary edema, but the evidence is from retrospective studies [24] [25] [26] .
Conclusion
The 
